ESSA Pharma Stock Forum

$ESSA Pharma (EPIX.US)$ Would not recommend this stock as their pipelines are all around the therapeutic strategies of masofaniten and its combinations which was not that successful in a recent Phase II trail.

$ESSA Pharma (EPIX.US)$ might wanna read the pipeline

$Verona Pharma (VRNA.US)$ $Safe & Green Development (SGD.US)$ $Globalstar (GSAT.US)$ $SRM Entertainment (SRM.US)$ $Silo Pharma (SILO.US)$ $ESSA Pharma (EPIX.US)$ $SAG Holdings (SAG.US)$ $Tenaya Therapeutics (TNYA.US)$ $Air Transport Services (ATSG.US)$ $Hanryu Holdings (HRYU.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $Singular Genomics (OMIC.US)$ $Nuwellis (NUWE.US)$ $Vast Renewables (VSTE.US)$
📊⚡️📊

$ESSA Pharma (EPIX.US)$
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma announced the termination of its Phase 2 clinical trial evaluating masofaniten combined with enzalutamide in metastatic castration-resistant prostate cancer patients. The decision came after a futility analysis showed the enzalutamide control arm performing better than historical controls and s...

$ESSA Pharma (EPIX.US)$
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 Esmo Congress

$ESSA Pharma (EPIX.US)$
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
ESSA Pharma presented updated Phase 1/2 clinical data for masofaniten (EPI-7386) in combination with enzalutamide at the 2024 ESMO Congress. The study focused on patients with metastatic castration-resistant prostate cancer(mCRPC). Key findings include:
- 88% of patients achieved PSA90
- 69% achieved PSA90 in less than 90 days
- 63% achieved PSA <0.2ng/mL
- After 15.2 ...

$ESSA Pharma (EPIX.US)$ funny how far off radar... soon...

$ESSA Pharma (EPIX.US)$ Director BERGER FRANKLIN M purchased 23,259 shares of Common Stocks on Nov 21, 2023 at an average price of $5.73 for a total value of $133.27K.